Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Peanut Allergy

Interventions

DRUG

IGNX001

IGNX001 given as a single subcutaneous dose on Day 1.

DRUG

Placebo

Placebo to IGNX001 given as a single subcutaneous dose on Day 1.

Trial Locations (4)

St Vincent's Sydney, Darlinghurst

Royal Melbourne Hospital, Parkville

Monash Health, Sleep, Allergy, and Immunology, Clayton

Fiona Stanley Hospital, Murdoch

All Listed Sponsors

lead

IgGenix Australia Pty Ltd

INDUSTRY

NCT06331728 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 | Biotech Hunter | Biotech Hunter